Multisystem inflammatory syndrome in adults (MIS-A): cardiovascular manifestations and in-hospital outcomes from two tertiary centers
Open Access
- 26 August 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1893335
Abstract
Background: Multisystem inflammatory syndrome in adults (MIS-A) is a rare, post-infectious hyperinflammatory condition characterized by multiorgan involvement and substantial cardiovascular morbidity. This study aimed to characterize the cardiovascular phenotype and clinical outcomes of adults with MIS-A and to compare findings between ICU and non-ICU patients. Methods: We conducted a multicenter retrospective case series of 22 hospitalized patients with a MIS-A phenotype across two university-affiliated clinical bases in Almaty, Kazakhstan (City Hospital No. 1 and City Hospital No. 7). Data were retrospectively abstracted from completed inpatient medical records after discharge or in-hospital death. Demographics, clinical manifestations documented during hospital days 0−3, baseline laboratory markers (first 24 h), treatments, and outcomes were extracted from medical records. Results: The median age was 43 years (IQR, 29−63; range 19−86), and 13/22 patients were female (59.1%). Fever (≥38 °C) was documented on 18/22 (81.8%). Mucocutaneous findings included rash in 12/22 (54.5%), enanthema in 10/22 (45.5%), and non-purulent conjunctivitis in 5/22 (22.7%). Echocardiography was available for 17/22 (77.3%); LVEF <50% was observed in 6/17 (35.3%). Gastrointestinal symptoms occurred in 7/22 (31.8%), neurologic manifestations in 8/22 (36.4%), and respiratory manifestations in 16/22 (72.7%). Inflammatory markers were markedly elevated, including C-reactive protein (median 181 mg/L, IQR, 95.4–245.0) and D-dimer (median 6.4 µg/mL FEU, IQR, 4.0–10.0). Leukocytosis occurred in 15/22 (68.2%), thrombocytopenia in 11/22 (50.0%), and lymphopenia in 8/22 (36.4%). Systemic corticosteroids were used on 14/22 (63.6%); ICU admission occurred on 11/22 (50.0%). In-hospital mortality was 5/22 (22.7%). Conclusion: Hospitalized patients with a MIS-A phenotype demonstrated severe hyperinflammation with frequent multiorgan involvement and meaningful in-hospital mortality. Early recognition and standardized assessment of organ dysfunction, particularly cardiovascular involvement, are essential.Keywords
This publication has 18 references indexed in Scilit:
- Particularités du syndrome inflammatoire multisystémique de l´adulte lié au SARS-CoV-2Pan African Medical Journal, 2025
- Multisystem Inflammatory SyndromeCardiology in Review, 2022
- Multisystem Inflammatory Syndrome in Adults: Case Finding Through Systematic Review of Electronic Medical RecordsClinical Infectious Diseases, 2022
- The emerging threat of multisystem inflammatory syndrome in adults (MIS-A) in COVID-19: A systematic reviewHeart & Lung, 2022
- Identification and description of patients with multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection using the Premier Healthcare DatabaseEpidemiology and Infection, 2022
- Editorial: Multisystem Inflammatory Syndrome in Adults (MIS-A) and the Spectrum of COVID-19Medical Science Monitor, 2021
- Clinical Characteristics of Multisystem Inflammatory Syndrome in AdultsJAMA Network Open, 2021
- Characteristics Associated With Multisystem Inflammatory Syndrome Among Adults With SARS-CoV-2 InfectionJAMA Network Open, 2021
- The Multisystem Inflammatory Syndrome in Adults With SARS-CoV-2 Infection—Another Piece of an Expanding PuzzleJAMA Network Open, 2021
- Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety dataVaccine, 2021